A 9-year-old boy developed progressive anthracycline-induced cardiomyopathy three months after completion of chemotherapy for osteosarcoma. Five months after completion of chemotherapy, at the age of 10 years, heart transplantation was performed. At 29 months since transplantation, the patient remains free of rejection and recurrence of osteosarcoma. (Level of Difficulty: Intermediate.)Peer reviewe
Aims: This study aims to assess subclinical changes in functional and morphological myocardial magne...
Background: Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can...
Background: Cardiotoxicity presenting as cardiomyopathy is a common side effect in cancer treatment ...
Publisher Copyright: © 2021 The AuthorsA 9-year-old boy developed progressive anthracycline-induced ...
Contains fulltext : 69207.pdf (publisher's version ) (Closed access)In a adolescen...
Anthracycline cardiotoxicity can induce dilated cardiomyopathy (DCM). Nine patients (four men) exper...
INTRODUCTION/OBJECTIVES: Cardiotoxic effects of the established therapy protocols can cause severe c...
Background: Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer...
Aims Cardiac dysfunction is a severe complication of anthracycline-containing anticancer therapy. Th...
The evolution of cancer therapies has led to marked improvement in survival of those affected by chi...
ObjectivesThe purpose of this study was to evaluate the clinical relevance of anthracycline-induced ...
BACKGROUND: Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, ...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of canc...
BackgroundAnthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disp...
Aims: This study aims to assess subclinical changes in functional and morphological myocardial magne...
Background: Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can...
Background: Cardiotoxicity presenting as cardiomyopathy is a common side effect in cancer treatment ...
Publisher Copyright: © 2021 The AuthorsA 9-year-old boy developed progressive anthracycline-induced ...
Contains fulltext : 69207.pdf (publisher's version ) (Closed access)In a adolescen...
Anthracycline cardiotoxicity can induce dilated cardiomyopathy (DCM). Nine patients (four men) exper...
INTRODUCTION/OBJECTIVES: Cardiotoxic effects of the established therapy protocols can cause severe c...
Background: Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer...
Aims Cardiac dysfunction is a severe complication of anthracycline-containing anticancer therapy. Th...
The evolution of cancer therapies has led to marked improvement in survival of those affected by chi...
ObjectivesThe purpose of this study was to evaluate the clinical relevance of anthracycline-induced ...
BACKGROUND: Three types of anthracycline-induced cardiotoxicities are currently recognized: acute, ...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of canc...
BackgroundAnthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disp...
Aims: This study aims to assess subclinical changes in functional and morphological myocardial magne...
Background: Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can...
Background: Cardiotoxicity presenting as cardiomyopathy is a common side effect in cancer treatment ...